| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 7.4% YoY consolidated revenue growth, reaching record ₹506.9 million. |
|---|---|
| Margins | EBITDA margin at 9.2%; pressured by RM costs and geopolitical freight. |
| Demand visibility | Strong in Chronic therapies; acute segment visibility impacted by weak monsoon. |
| Management confidence | Balanced; optimistic on segment growth but cautious regarding external cost pressures. |
Growth
Consolidated revenue grew 7.4% YoY; Stomatological and Gastrointestinal segments showed strong performance at 34.8% and 30.3% growth respectively.
Outlook
Management plans to reduce debt by approximately ₹120 Cr during FY27, having already repaid ₹65 Cr in H1.
Risks
Substantial ₹13 Cr additional freight impact from Middle East conflict; US FDA compliance at Plant 2 remains a critical oversight.
Last quarter's promises, checked
Delivered
- Europe 'very good consistent performance' → Regulated markets +21.1%; Europe/UK 'strong momentum' (= BEAT)
- Margins to 'keep improving QoQ' from 8.8% consol Q1 → 9.2% EBITDA, basis unstated (= BEAT)
Partly delivered
- Repay ₹110 Cr in FY27 → ₹65 Cr repaid H1; FY27 target now ₹120 Cr (= PARTIAL)
Missed
- 'Double-digit EBITDA margins for the year' (aim) → 9.2% EBITDA margin (= MISS)
- USFDA audit 'in next couple of months' (28 Jul) → Plant 2 still unresolved (= MISS)
Earnings Call Transcript filed with NSE, NSE: INDOCO. Summary written with AI assistance from the document.
Indoco Remedies Ltd: key numbers
- Share price
- ₹213.75
- Market cap
- ₹1,973 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 61.8×Sector 46.1×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Q2 FY27 Results: Turns Profitable, Net Profit ₹19.5 Cr
Indoco Remedies Ltd reported revenue from operations of ₹506.9 Cr (+7.4% YoY) and net profit of ₹19.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹19.5 Cr
Indoco Remedies Employee Stock Options
Indoco Remedies allotted 14,850 ESOP shares to its Employees Welfare Trust under the 2022 ESOP plan. The allotment is at face value with no transaction price.
Indoco Remedies Other Announcement
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies Board Meeting Date
Indoco Remedies intimated a board meeting on 27 Oct 2026 to approve Q1 FY27 standalone and consolidated results. Trading window remains closed until 29 Oct 2026.
Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr
Indoco Remedies Limited is incorporating a new wholly owned subsidiary, Warren Lifesciences Private Limited, for a cash investment of ₹0.01 Crore.
- Value
- ₹0.01 Cr